Homozygous Familial Hypercholesterolemia (HoFH) Clinical Trial
Official title:
An Open-Label Long-Term Extension to the Randomized, Double-blind, Placebo-controlled, Multi-center, Cross-over Study of Rosuvastatin in Children and Adolescents (Aged 6 to <18 Years) With Homozygous Familial Hypercholesterolemia (HoFH)
The purpose of the study is to evaluate the safety of Rosuvastatin in Children and Adolescents with Homozygous Familial Hypercholesterolemia.
This is a long-term extension (LTE) to the randomized, double-blind, cross-over study of
rosuvastatin 20 mg once daily (QD) versus placebo QD in children and adolescents (aged from 6
to <18 years) with homozygous familial hypercholesterolemia (HoFH) (Study D3561C00004).
The study is designed to assess the long-term safety and tolerability of rosuvastatin 20 mg
in pediatric patients with HoFH.
In this study all patients will receive rosuvastatin 20 mg QD. Investigators will also be
permitted to titrate the dose of rosuvastatin from 20 to 40 mg per day if they feel it is
warranted to more aggressively treat patients' elevated LDL-C levels. This up-titration will
not be permitted in Asian patients. Pharmacokinetic data of the trough plasma exposure of
rosuvastatin will also be assessed for the pediatric patients with HoFH taking a daily dose
of rosuvastatin 40 mg.
The primary outcome measures to be assessed include 1) Adverse events, including:
- The frequency and severity of adverse events,
- Rate of discontinuations due to adverse events,
- Abnormal serum and urine laboratory values, electrocardiograms (ECGs), physical
examinations, and vital signs; and 2) Assessments of growth.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04080050 -
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501
|
||
| Completed |
NCT02226198 -
A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia
|
Phase 3 | |
| Terminated |
NCT02651675 -
A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)
|
Phase 1/Phase 2 | |
| Completed |
NCT04148001 -
Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Patients
|